Table 3.
Overview of human clinical trials of HER2 targeting radiolabeled nanobodies in breast cancer patients. Status April 2020
| Nanobody | Radioisotope | Diagnostic/therapy | Trial no. | Phase | Patients | First posted | Outcome | Reference |
|---|---|---|---|---|---|---|---|---|
| 2Rs15d | 68Ga | PET | EudraCT 2012-001135-31 | I | 20 | 2012 | Favourable biodistribution, high tumor to background ratio, fast blood clearance no signs of toxicity, urinary bladder as dose limiting organ | [140] |
|
EudraCT 2015-002328-24 |
II | 30 |
07/2015 11/2017 |
Ongoing | Nonpublished | |||
| NCT03924466 | 20 | 04/2019 | Ongoing | Nonpublished | ||||
| 131I | SPECT & Therapy | NCT02683083 | I | 9 | 02/2016 | A high tumor to background rate, fast blood clearance, no signs of toxicity | [149] | |
| 99mTc | SPECT | NCT04040686 | I | 10 | 08/2019 | Ongoing | Nonpublished | |
| MM-302 | 64Cu | PET and therapy | NCT02735798 | I | 0 | 04/2016 | Tumor accumulation vary between and within patients, background uptake in liver and spleen withdrawn | [143] |